Antiviral Compounds Bind to a Specific Site Within Human Rhinovirus
The approximately 100 serotypes of human rhinovirus (HRV) , the most commonly isolated virus from those suffering from an upper respiratory infection (common cold), represent a formidable therapeutic challenge . A number of structurally unrelated compounds (Figure 39.1) have been shown to inhibit HRV uncoating (i.e., the release of viral RNA into the cytosol) as a result of site-specific binding to virions. Recently, X-ray crystallographic analysis of disoxaril, [5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3methylisoxazole]=HRV(type 14) complexes has identified the specific binding site in the viral capsid [3,4]. In this chapter the molecular details and biological consequences of the binding of several antiviral compounds to HRV-14 are discussed.
KeywordsCysteine Phenyl Pyridine Serine Methionine
Unable to display preview. Download preview PDF.
- 4.Badger J, Minor I, Kremer MJ, Oliveira MA, Smith TJ, Griffith JP, Guerin DMA, Krishnaswamy S, Luo M, Rossmann MG, McKinlay MA, Diana GD, Dutko FJ, Fancher M, Rueckert RR, Heinz BA (1988) Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Nati Acad Sci USA 85: 3304–3308CrossRefGoogle Scholar
- 9.Palmenberg AC (1988) Sequence alignments of picornaviral capsid proteins. International Conference on Molecular Biology of Picornaviruses, ICN—UCI, Abstr, Jan 1988Google Scholar
- 18.Otto MJ, Diana GD, McKinlay MA, Felock P, Fancher M (1987) In vitro antipicornavirus activity of WIN 54954, a new analog of disoxaril with improved spectrum and potency. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, Abstr No 491.Google Scholar
- 20.Al-Nakib W, Higgins PG, Tyrrell DAJ, Barrow IG, Taylor N, Andries K (1987) Tolerance and prophylactic efficacy of a new antirhinovirus compound, R61837. Seventh International Congress of Virology, Edmonton, Alberta, Canada, Abstr No 32. 3Google Scholar